Targets › IDH2
7 programs from 7 companies in 31 trials: 13 Phase 1, 12 Phase 2, 6 Phase 3; Oncology, Hematology, Gastroenterology; next expected readout Nov 2026.
Catalyzes the NADP(+)-dependent oxidative decarboxylation of isocitrate (D-threo-isocitrate) to 2-ketoglutarate (2-oxoglutarate), playing a role in intermediary metabolism and energy production. Can also use 2-oxoglutarate as substrate and catalyze the reduction of 2-oxoglutarate to R-2-hydroxyglutarate. (UniProt, P48735)
Open in Phaseline: the race on IDH2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hutchmed | HMPL-306 IDH1/IDH2 inhibitor | IDH1, IDH2 | Phase 3 | Acute Myeloid Leukemia; Gliomas Harboring IDH1 and/or IDH2 Mutations | Dec 2026 |
| Servier | Vorasidenib (S095032) IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1, IDH2 | Phase 3 | Residual or Recurrent Grade 2 IDH Mutant Glioma | Oct 2030 |
| Institut de Recherches Internationales Servier (I.R.I.S.) | Vorasidenib IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1, IDH2 | Phase 2 | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation; Severe Hepatic Impairment; Grade 2 Glioma; Astrocytoma, IDH-Mutant, Grade 3 … | Nov 2026 |
| M.D. Anderson Cancer Center | Enasidenib Mesylate Isocitrate dehydrogenase [NADP], mitochondrial inhibitor | IDH2 | Phase 2 | Acute Myeloid Leukemia; Acute Bilineal Leukemia | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | TQB3455 tablet IDH2 mutant enzyme inhibitor | IDH2 | Phase 1 | Acute Myeloid Leukemia (AML) | Dec 2026 |
| Eli Lilly | LY3410738 Covalent isocitrate dehydrogenase (IDH) inhibitor | IDH1, IDH2 | Phase 1 | Acute Myeloid Leukemia (AML); Cholangiocarcinoma | May 2027 |
| Bristol-Myers Squibb | Enasidenib (AG-221) Isocitrate dehydrogenase [NADP], mitochondrial inhibitor | IDH2 | Phase 1 | Leukemia, Myeloid, Acute; Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Myelodysplastic Syndromes … | – |
Acute Myeloid Leukemia (7) Acute Myeloid Leukemia (AML) (3) Cholangiocarcinoma (1) Leukemia, Myeloid, Acute (1) Recurrent Acute Myeloid Leukemia (1) Myelodysplastic Syndromes (1) Myelodysplastic Syndrome (1) T-cell Lymphoma (1) Metastatic Chondrosarcoma (1) Clonal Cytopenia of Undetermined Significance (1) Previously Untreated Relapsed Refractory Acute Myeloid Leukemia (1) Newly Diagnosed Acute Myeloid Leukemia (AML) (1)
small molecule (7)
Eli Lilly (1) Bristol-Myers Squibb (1) Servier (1) M.D. Anderson Cancer Center (1) Hutchmed (1) Institut de Recherches Internationales Servier (I.R.I.S.) (1) Chia Tai Tianqing Pharmaceutical Group (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.